ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
AstraZeneca’s immunotherapy fails in key lung cancer trial
pharmaphorum
November 27, 2018AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck & Co is enjoying huge sales success with Keytruda.
Pharma Sources Insight January 2025
